Skip to main content

Advertisement

Log in

Clinical effect of Maixuekang Capsule (脉血康胶囊) on long-term prognosis in patients with acute coronary syndrome after percutaneous coronary intervention

  • Original Article
  • Published:
Chinese Journal of Integrative Medicine Aims and scope Submit manuscript

Abstract

Objective

To study the changes of adenosine diphosphate (ADP)-induced platelet aggregation rate, and evaluate the effects of Maixuekang Capsule (脉血康胶囊, MKC) on platelet aggregation rate and long-term prognosis of patients with acute coronary syndrome after percutaneous coronary intervention (PCI).

Methods

A total of 236 patients with acute coronary syndrome, who received successful PCI, were randomly assigned to a trial group (116 cases) and a control group (120 cases) according to random numbers; treatment allocation occurred when the participants met the inclusion criteria and signed the informed consent forms. In the trial group, the patients were treated with MKC combined with routine medication, and in the control group the patients were treated with routine medication. The therapeutic course for the two groups was 12 months and the follow-up was 12 months. The levels of ADP-induced platelet aggregation rate and serum high-sensitive C-reactive protein (hs-CRP) were determined before PCI, 12 h and 30 days after PCI. In the meantime, the incidence of cardio-/cerebrovascular events was recorded during the 12-month follow-up.

Results

Compared with before PCI, the levels of ADP-induced platelet aggregation rate and serum hs-CRP were significantly higher at 12 h after PCI (P<0.05). They were significantly reduced after 30-day-treatment of MKC, showing statistical differences when compared with those in the control group (P<0.05). During the 12-month follow-up, the incidence of cardio-/cerebrovascular events was significantly lower in the trial group than in the control group (6.9% vs. 12.5%, P<0.01).

Conclusions

ADP-induced platelet aggregation function was significantly elevated after PCI. MKC improved the prognosis of patients with acute coronary syndrome, possibly through inhibiting the platelet aggregation, fighting against inflammation, and protecting the vascular endothelial function.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Lin Y, Song XT, Meng K, Tian R, Yuan F, Chen X, et al. Analysis and evaluation of stent thrombosis induced acute coronary syndrome after drug eluting stent deployment. J Cardiovasc Pulmon Dis (Chin) 2008;27:144–147.

    Google Scholar 

  2. Xue M, Yin HJ, Wu CF, Ma XJ, Guo CY, Huang Y, et al. Effect of Chinese drugs for activating blood circulation and detoxifying on indices of thrombosis, inflammatory reaction, and tissue damage in a rabbit model of toxin-heat and blood stasis syndrome. Chin J Integr Med 2013;19:42–47.

    Article  CAS  PubMed  Google Scholar 

  3. Chen KJ, Shi DZ, Xu H, LÜ SZ, Li TC, Ke YN, et al. XS0601 reduces the incidence of restenosis: a prospective study of 335 patients undergoing percutaneous coronary intervention in China. Chin Med J 2006;119:6–13.

    CAS  PubMed  Google Scholar 

  4. Miu YX. Clinical observation of Maixuekang Capsule treatment on 60 people who has angina. Guangxi Med J (Chin) 2008;30:661–662.

    Google Scholar 

  5. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-STelevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 2007;50:e1–e157.

    Article  PubMed  Google Scholar 

  6. Committee of Cardiovascular Disease, Chinese Association of Integrated Traditional Chinese and Western Medicine. Standard of syndrome differentiation of coronary heart disease in Chinese medicine. Chin J Integr Tradit West Med (Chin) 1991;11:257.

    Google Scholar 

  7. Wang J, Chen KJ, Weng WL, Qian ZH, Wang Y, Liu JG, et al. Research on the diagnostic criteria of blood-stasis symptom-complex. Chin J Integr Tradit West Med (Chin) 1988;10:580–585.

    Google Scholar 

  8. Hamon M. Mechanism of thrombosis: physiopathology, role of thrombin and its inhibition by modern therapies. Arch Mal Coeur Vaiss 2006;99:5–9.

    PubMed  Google Scholar 

  9. Meng BB, LÜ CZ, Jiang YY. Direct Thrombin inhibitors and the application of them in cardiovascular disease. Chin J Cardiovasc Rev (Chin) 2006;4:72–75.

    Google Scholar 

  10. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293:2126–2130.

    Article  CAS  PubMed  Google Scholar 

  11. Gao LJ, Chen J, Chen JL. The pathophysiological mechanism and clinical research progress of coronary artery stent thrombosis. Chin Circulat J (Chin) 2007;22:396–398.

    CAS  Google Scholar 

  12. Wang TH, Bhatt DL, Topol EJ. Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J 2006;27:647–654.

    Article  PubMed  Google Scholar 

  13. Wiviott SD, Antman EM. Clopidogrel resistance: a new chapter in a fast-moving story. Circulation 2004;109:3064–3067.

    Article  PubMed  Google Scholar 

  14. Wenaweser P, Hess O. Stent thrombosis is associated with an impaired response to antiplatelet therapy. J Am Coll Cardiol 2005;46:CS5–CS6.

    Article  PubMed  Google Scholar 

  15. Wang D, Paria BC, Zhang Q, Karpurapu M, Li Q, Gerthoffer WT, et al. A role for Gab1/SHP2 in thrombin activation of PAK1: gene transfer of kinase-dead PAK1 inhibits injuryinduced restenosis. Circ Res 2009;104:1066–1075.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  16. Jormalainen M, Vento AE, Lukkarinen H, Kääpä P, Kytö V, Lauronen J, et al. Inhibition of thrombin during reperfusion improves immediate postischemic myocardial function and modulates apoptosis in a porcine model of cardiopulmonary bypass. J Cardiothorac Vasc Anesth 2007;21:224–231.

    Article  CAS  PubMed  Google Scholar 

  17. Mo W, Zhang YL, Chen HS, Wang LS, Song HY. A novel hirudin derivative characterized with anti-platelet aggregations and thrombin inhibition. J Thromb Thrombolysis 2009;28:230–237.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Shu-zheng Lv  (吕树铮).

Additional information

Supported by the Key Projects in the National Science and Technology Pillar Program during 11th Five-Year Plan Period (No. 2006BAI01A02); the Capital Medical Development Fund (No. SF-2009-I-09); and the President of Science and Technology Development Fund of Beijing Anzhen Hospital (No. 2013F01)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ge, Cj., Yuan, F., Feng, Lx. et al. Clinical effect of Maixuekang Capsule (脉血康胶囊) on long-term prognosis in patients with acute coronary syndrome after percutaneous coronary intervention. Chin. J. Integr. Med. 20, 88–93 (2014). https://doi.org/10.1007/s11655-013-1580-x

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11655-013-1580-x

Keywords

Navigation